Carlyle's Abingworth Raised $356M for New Clinical Co-Development Co-Investment Fund
Portfolio Pulse from Benzinga Newsdesk
Abingworth, a life sciences investment group under Carlyle (NASDAQ:CG), has closed its new Clinical Co-Development Co-Investment Fund at $356 million, exceeding its target of $300 million. This, along with the Abingworth Clinical Co-Development Fund 2, means Abingworth has raised over $930 million in new funds since 2021 to invest in late-stage clinical programs globally.
October 30, 2023 | 8:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Carlyle's Abingworth has successfully raised significant funds for investment in late-stage clinical programs, which could potentially lead to increased revenues and growth for Carlyle.
The successful fundraising by Abingworth, a part of Carlyle, indicates a strong investor confidence in their strategy. This could potentially lead to increased investments in late-stage clinical programs, which if successful, could result in increased revenues and growth for Carlyle.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100